1
|
de Mazancourt P, Quélin F, Flaujac C, de Raucourt E, Guillet B, Bauduer F, Ernest V, Beurrier P, Avril A, d'Oiron R, Biron-Andréani C, Meunier S, Dargaud Y. A focus on dominant negative variants in a series of 170 heterozygous FXI-deficient patients. Haemophilia 2023. [PMID: 37252892 DOI: 10.1111/hae.14802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Revised: 05/11/2023] [Accepted: 05/11/2023] [Indexed: 06/01/2023]
Abstract
INTRODUCTION Dominant-negative effects have been described for 10 F11 variants in the literature. AIM The current study aimed at identifying putative dominant-negative F11 variants. MATERIAL AND METHODS This research consisted in a retrospective analysis of routine laboratory data. RESULTS In a series of 170 patients with moderate/mild factor XI (FXI) deficiencies, we identified heterozygous carriers of previously reported dominant-negative variants (p.Ser243Phe, p.Cys416Tyr, and p.Gly418Val) with FXI activities inconsistent with a dominant-negative effect. Our findings also do not support a dominant-negative effect of p.Gly418Ala. We also identified a set of patients carrying heterozygous variants, among which five out of 11 are novel, with FXI activities suggesting a dominant-negative effect (p.His53Tyr, p.Cys110Gly, p.Cys140Tyr, p.Glu245Lys, p.Trp246Cys, p.Glu315Lys, p.Ile421Thr, p.Trp425Cys, p.Glu565Lys, p.Thr593Met, and p.Trp617Ter). However, for all but two of these variants, individuals with close to half normal FXI coagulant activity (FXI:C) were identified, indicating an inconstant dominant effect. CONCLUSION Our data show that for some F11 variants recognized has having dominant-negative effects, such effects actually do not occur in many individuals. The present data suggest that for these patients, the intracellular quality control mechanisms eliminate the variant monomeric polypeptide before homodimer assembly, thereby allowing only the wild-type homodimer to assemble and resulting in half normal activities. In contrast, in patients with markedly decreased activities, some mutant polypeptides might escape this first quality control. In turn, assembly of heterodimeric molecules as well as mutant homodimers would result in activities closer to 1:4 of FXI:C normal range.
Collapse
Affiliation(s)
- Philippe de Mazancourt
- UMR1179, Université de Versailles-Saint-Quentin, Montigny le Bretonneux, France
- Laboratoire de Biologie Moléculaire, Hôpital A. Paré, APHP.Paris-Saclay, Boulogne-Billancourt, France
| | - Florence Quélin
- Département de Recherche Clinique, CH Versailles, Le Chesnay, France
| | - Claire Flaujac
- Laboratoire de biologie médicale, secteur hémostase, centre hospitalier de Versailles (André Mignot), Le Chesnay, France
| | - Emmanuelle de Raucourt
- Centre de Ressources et de Compétences Maladies Hémorragiques Constitutionnelles, CH de Versailles, Le Chesnay, France
| | - Benoît Guillet
- Centre de Traitement des maladies hémorragiques, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France
| | - Frédéric Bauduer
- Service d'Hématologie, Centre Hospitalier de la Côte Basque, Bayonne, and UMR 5199 PACEA, Université de Bordeaux, Pessac, France
| | - Vincent Ernest
- Laboratoire d'Hématologie, CHU la Timone, Marseille, France
| | | | - Aurélie Avril
- UMR1179, Université de Versailles-Saint-Quentin, Montigny le Bretonneux, France
| | - Roseline d'Oiron
- Centre de Traitement de l'Hémophilie - CRTH - CHU Paris-Sud - Hôpital de Bicêtre, APHP.Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Christine Biron-Andréani
- Centre de Traitement de l'Hémophilie (CTH) Centre de Ressources et de Compétences Maladies Hémorragiques Constitutionnelles (CRC-MHC) - Hôpital St-Eloi, CHU Montpellier, Montpellier, France
| | - Sandrine Meunier
- Hospices civils de Lyon; Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, CHU de Lyon, Lyon, France
| | - Yesim Dargaud
- Hospices civils de Lyon; Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, CHU de Lyon, Lyon, France
| |
Collapse
|